PCMC
BMRN icon

Planning Capital Management Corporation’s BioMarin Pharmaceuticals BMRN Stock Holding History

Planning Capital Management Corporation’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$12K Hold
171
– – 0.01% 411
2024
Q2 		$14.1K Buy
+171
New +$14.2K 0.01% 356

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Planning Capital Management Corporation's BMRN Position: Q3 2024 in Review

Planning Capital Management Corporation held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2024 at 171 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #411.

Planning Capital Management Corporation first reported a position in BMRN in Q2 2024 and has held it in 2 quarters since. The position peaked at $14.1K in Q2 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Planning Capital Management Corporation held 171 shares of BioMarin Pharmaceuticals worth $12K as of Q3 2024.
  • Planning Capital Management Corporation left its BioMarin Pharmaceuticals share count unchanged in Q3 2024.
  • BioMarin Pharmaceuticals made up 0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #411 holding.
  • Planning Capital Management Corporation first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's BioMarin Pharmaceuticals position peaked at $14.1K in Q2 2024.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.